Ordering Recommendation

Diagnostic testing for alpha thalassemia in fetus with suggestive clinical findings or at risk for alpha thalassemia due to familial HBA1/HBA2 deletions or hemoglobin Constant Spring (HbCS) variant. Use to detect common as well as rare and novel deletions or duplications of the alpha globin gene cluster and the HbCS variant.

Mnemonic

HBA DDCSFE

Methodology

Multiplex Ligation-dependent Probe Amplification with Sanger sequencing confirmation of HbCS

Performed

Varies

Reported

10 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Cultured amniocytes or Cultured CVS  
AND Maternal Whole Blood Specimen: Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).

Specimen Preparation

Cultured Amniocytes or Cultured CVS: Transfer cultured amniocytes or cultured CVS to two T-25 flasks at 80 percent confluence. (Min: one T-25 flask at 80% confluence). Backup cultures must be retained at the client's institution until testing is complete. If the client is unable to culture amniocytes or CVS, this can be arranged by contacting ARUP Client Services at (800) 522-2787. Please contact an ARUP genetic counselor at (800) 242-2787 ext. 2141 prior to test submission.
Maternal Whole Blood Specimen
: Transport 2 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature

Cultured Amniocytes or CVS: CRITICAL ROOM TEMPERATURE. Must be received within 48 hours of collection due to viability of cells.
Maternal Whole Blood Specimen
: Room temperature.

Unacceptable Conditions
Remarks

Please contact an ARUP genetic counselor at 800-242-2787 x2141 prior to sample submission. Patient History Form is available on the ARUP Web site or by contacting ARUP Client Services at (800) 522-2787

Stability

Cultured Amniocytes or Cultured CVS: Room temperature: 48 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
Maternal Whole Blood Specimen
: Room temperature: 7 days; Refrigerated: 1 month; Frozen: Unacceptable

Reference Interval

By report

Interpretive Data

Background Information: Alpha Globin (HBA1 and HBA2) Deletion/Duplication
Characteristics:
Decreased or absent synthesis of the hemoglobin (Hb) alpha-chain resulting in clinical presentations ranging from asymptomatic silent carriers to severe anemia and fetal lethality. Alpha thalassemia silent carrier commonly results from deletion of a single alpha globin gene (-a/aa) and is clinically asymptomatic. Alpha thalassemia trait may be caused by deletion of a single alpha globin gene from both chromosomes (-a/-a), or deletion of the HBA1 and HBA2 globin genes from the same chromosome (--/aa). Heterozygosity for Hb Constant Spring (HbCS) is usually asymptomatic but may be associated with mild microcytic anemia. Homozygous HbCS is characterized by overt hemolytic anemia, jaundice and splenomegaly. Hemoglobin H disease occurs due to inactivation of three alpha globin genes and results in hemolysis with Heinz bodies, moderate anemia, and splenomegaly. Hb Bart hydrops fetalis syndrome results from deletion of all four alpha globin genes (--/--) and is lethal in the fetal or early neonatal period. Alpha globin gene duplication results in three or more active alpha globin genes on a single chromosome.
Epidemiology: Carrier frequency of alpha thalassemia in African, African-American (1:3), Mediterranean (1:30-50), Middle Eastern, Southeast Asian (1:20).
Inheritance: Autosomal recessive.
Cause: Pathogenic variants in the alpha globin gene cluster (HBZ, HBM, HBA2, HBA1, HBQ1) or regulatory region.
Clinical Sensitivity: Varies by ethnicity, at least 90 percent.
Methodology: Multiplex ligation-dependent probe amplification (MLPA) for the HBZ, HBM, HBA2, HBA1, and HBQ1 genes, the HS-40 regulatory region, and Hb Constant Spring (HbCS) HBA2 c.427T>C; p.Ter143Gln. To determine copy number of HbCS in absence of a concurrent deletion of HBA2, PCR and bidirectional sequencing for HbCS is performed.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Specific breakpoints of large deletions/duplications will not be determined; therefore, it may not be possible to distinguish variants of similar size. Non-deletional variants within the coding or regulatory regions of the alpha globin cluster genes, other than HbCS, will not be detected. Fetuses carrying both a deletion and duplication within the alpha globin gene cluster may appear to have a normal number of alpha globin gene copies. Rare syndromic or acquired forms of alpha thalassemia associated with ATRX gene variants will not be detected.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Compliance Category

Laboratory Developed Test (LDT)

Note

If a concurrent deletion of HBA2 is not identified, PCR and bidirectional sequencing for the HbCS copy number will be performed. Additional charges apply.

Hotline History

N/A

CPT Codes

81269; 81265; if reflexed, add 81257

Components

Component Test Code* Component Chart Name LOINC
0050548 Maternal Contamination Study Fetal Spec 59266-7
0050612 Maternal Contam Study, Maternal Spec 31208-2
3003658 Specimen HBA DDCSFE 66746-9
3003659 HBA DDCSFE Interpretation 55234-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • A globin
  • Alpha globin gene analysis
  • Alpha globin mutations
  • Alpha thalassemia
Alpha Thalassemia (HBA1 and HBA2) Deletion/Duplication with reflex to Hb Constant Spring, Fetal